This case report highlights a potential association between short-term fenfluramine-phentermine use and the development of restrictive cardiomyopathy due to endocardial fibrosis.
May warrant vigilance for cardiomyopathy with fenfluramine-phentermine; leaves open causality in this single case.
To the Editor: It has been previously reported that valvular heart disease may be associated with the use of anorectic drugs.1 We report a case of restrictive cardiomyopathy due to endocardial fibrosis after short-term use of fenfluramine–phentermine. A 35-year-old woman was hospitalized for congestive heart failure. Five months earlier she had begun taking 10 mg of fenfluramine three times a day and 15 mg of phentermine once a day, prescribed at her request because of obesity (height, 1.77 m; weight, 94.5 kg; body-mass index [calculated as the weight in kilograms divided by the square of the height in meters], 30.3). . . .
No takes yet. Share an insight, caveat, or question.
Fowles et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: